This Week in Rheumatology — Jul 31, 2026

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning critical advances in systemic lupus erythematosus, prognostic biomarkers in systemic sclerosis, and evolving therapeutic strategies in inflammatory arthritis, vasculitis, and autoinflammatory conditions. Let's dive in.

We begin this week with systemic lupus erythematosus, focusing on how we risk-stratify our patients across different clinical scenarios, from pregnancy planning to daily functional safety. First, in a study published in RMD Open, researchers evaluated the impact of antiphospholipid antibodies and their specific profiles on pregnancy outcomes [5]. Looking at a cohort of four hundred and forty-one pregnancies in patients with lupus, the investigators found that overall, being positive for antiphospholipid antibodies more than doubled the risk of adverse pregnancy outcomes, such as fetal death or severe pre-eclampsia. But the real clinical takeaway lies in the antibody profiles. The risk of adverse outcomes was predominantly driven by IgG-positive anticardiolipin, IgG-positive anti-beta-2 glycoprotein I, and lupus anticoagulant, whereas IgM isotypes did not significantly increase risk. Crucially, the combination of lupus anticoagulant plus IgG isotypes of anticardiolipin or anti-beta-2-glycoprotein I represented the highest-risk profile, nearly quadrupling the rate of adverse outcomes. This tells us that when we counsel our lupus patients who are planning a pregnancy, we must look beyond a simple positive or negative screen and specifically risk-stratify based on these high-risk IgG and lupus anticoagulant combinations to tailor our monitoring and preventive therapies. Moving from pregnancy to longitudinal disease monitoring, a study in Rheumatology Oxford addresses a common clinical dilemma: how to manage patients with prolonged serologically active but clinically quiescent lupus [6]. Clinicians often wonder whether persistent elevations in double-stranded DNA antibodies or low complement levels in an otherwise asymptomatic patient warrant concern. By analyzing more than five hundred visits over a mean of three-point-three years, researchers found that nearly two-thirds of these clinically quiet patients eventually experienced at least one clinical flare. A visit-by-visit analysis revealed that rising IgG anti-double-stranded DNA and falling C3 levels were strong, independent predictors of a flare at the subsequent visit. This underscores the clinical value of tracking serological trends even in patients who appear completely well, suggesting that a downward trend in complement or an upward trend in double-stranded DNA should prompt closer clinical follow-up rather than reassurance alone. Finally, we must consider the impact of comorbidities on the physical safety of our patients with lupus. A large retrospective cohort study published in Lupus Science and Medicine utilized the TriNetX United States Collaborative Network to investigate the relationship between comorbid fibromyalgia and musculoskeletal risks in patients with lupus [8]. After matching over twenty-three thousand patients with lupus and comorbid fibromyalgia to an equal number of lupus-only controls, the researchers found that those with comorbid fibromyalgia had a thirty-eight percent increased risk of falls, a fifty-three percent increased risk of recurrent falls, and significantly elevated risks for both vertebral and general osteoporotic fractures over five years. This is a vital reminder that fibromyalgia in our lupus patients is not just a source of chronic pain; it represents a tangible physical hazard. We should actively incorporate fibromyalgia evaluations into our fall risk assessments and implement early, multidisciplinary bone-protective and fall-prevention strategies for this vulnerable subgroup.

Next, we turn our attention to systemic sclerosis, where two new papers offer valuable tools for prognostic stratification and understanding organ-specific risks. In Annals of the Rheumatic Diseases, an analysis of the landmark SENSCIS trial evaluated circulating biomarkers in patients with systemic sclerosis-associated interstitial lung disease [4]. The researchers identified that a baseline level of Krebs von den Lungen-6, or KL-6, greater than one thousand units per milliliter was a powerful predictor of rapid lung function decline, with these patients experiencing more than double the rate of decline in forced vital capacity over fifty-two weeks compared to those with lower baseline levels. Furthermore, the study shed light on the mechanisms of nintedanib, showing that it significantly reduced levels of the epithelial dysfunction marker CA-125 and the collagen synthesis marker pro-C6. In fact, nearly half of nintedanib's beneficial effect on forced vital capacity was directly attributed to this reduction in CA-125. In practice, using a clear clinical threshold for KL-6 can help us identify patients at high risk for rapid pulmonary progression who require aggressive upfront management. Complementing these pulmonary findings, a study in Rheumatology Oxford explored the role of serum Vascular Cell Adhesion Molecule-1, or VCAM-1, in patients from the Australian Scleroderma Cohort Study [10]. The investigators found that patients with VCAM-1 levels in the highest quartile had more than double the risk of mortality. Interestingly, these high VCAM-1 levels did not correlate with traditional risk factors like age, disease duration, or interstitial lung disease. Instead, they were strongly associated with a distinct vasculopathic phenotype, including pulmonary arterial hypertension, systemic sclerosis-attributable myocardial disease, and digital ulcers. In cause-specific mortality analyses, patients in the highest quartile of VCAM-1 had a threefold risk of dying from pulmonary arterial hypertension or myocardial disease. This suggests that VCAM-1 is not merely a marker of general inflammation, but an independent driver of vascular pathology that could help us screen for and monitor life-threatening cardiovascular and pulmonary vascular complications.

Our third theme explores new horizons in targeted therapies and diagnostic precision across inflammatory arthritis, vasculitis, and autoinflammatory conditions. In giant cell arteritis, the question of how long to continue targeted therapy is a frequent clinical challenge. A study in Annals of the Rheumatic Diseases presented two-year data from the SELECT-GCA trial, comparing the continuation of upadacitinib fifteen milligrams daily against switching to a placebo after achieving remission at one year [1]. The results were striking: patients who continued upadacitinib experienced dramatically fewer disease flares—just over seven percent compared to nearly sixty percent in the withdrawal group. Furthermore, those continuing upadacitinib were far more likely to maintain glucocorticoid-free remission and had zero median glucocorticoid exposure during the second year, compared to over one thousand milligrams in the withdrawal group. With no new safety signals reported over the two years, these findings strongly support the extended use of upadacitinib fifteen milligrams to maintain remission and minimize steroid toxicity in giant cell arteritis. In psoriatic arthritis, addressing obesity is a major therapeutic hurdle, as excess adipose tissue can dampen the effectiveness of biologic therapies. A prospective, propensity score-matched study in RMD Open evaluated the concurrent initiation of the dual GIP and GLP-1 receptor agonist tirzepatide alongside biologic therapy in obese psoriatic arthritis patients [2]. At six months, patients receiving tirzepatide not only achieved a significant reduction in body mass index but also demonstrated substantially better patient-reported outcomes, with more than double the rates of achieving an acceptable symptom state and a low health assessment questionnaire score compared to those on biologics alone. They also achieved significantly better skin clearance and greater reductions in C-reactive protein. This study suggests that treating obesity actively and concurrently with biologics, rather than as an afterthought, can synergistically improve both clinical and patient-reported outcomes in psoriatic arthritis. In early rheumatoid arthritis, identifying patients at risk for rapid joint damage remains a priority. A study from the French national ESPOIR cohort, published in Arthritis and Rheumatology, investigated the clinical utility of anti-carbamylated fibrinogen autoantibodies, or ACa-Fib, of both IgG and IgA isotypes [7]. The researchers found that these antibodies were present in a notable portion of patients who were negative for anti-cyclic citrullinated peptide, or anti-CCP. High baseline levels of ACa-Fib IgG were associated with a significantly increased risk of rapid radiographic progression over twenty-four months. Meanwhile, ACa-Fib IgA levels, which remained stable over time, were strongly linked to smoking history and nearly doubled the risk of structural progression. These findings suggest that testing for ACa-Fib isotypes can provide valuable, independent prognostic information, helping us identify patients with early, aggressive disease who might otherwise appear lower-risk on standard antibody panels. We also saw major diagnostic progress in the field of systemic autoinflammatory diseases. A study in Arthritis and Rheumatology analyzed over fifty-five hundred and thirty patients referred to a national reference center to characterize the role of acquired somatic mutations, or mosaicism, in these conditions [3]. Using deep next-generation sequencing, they diagnosed a systemic autoinflammatory disease in over seven percent of the cohort, and remarkably, more than one in five of these diagnosed patients carried a mosaic variant. The majority of these were VEXAS syndrome, followed by cryopyrin-associated periodic syndromes, or CAPS, and TNF receptor-associated periodic syndrome, or TRAPS. This study also reported the first-ever case of vertical transmission of TRAPS due to gonosomal mosaicism and noted that twenty percent of patients with late-onset mosaic CAPS developed AA amyloidosis. This landmark cohort highlights that somatic mosaicism is a frequent, under-recognized driver of late-onset autoinflammatory diseases, and underscores the necessity of deep sequencing in older patients presenting with unexplained systemic inflammation to prevent complications like amyloidosis. Finally, in pediatric rheumatology, we look at refractory Kawasaki disease. A systematic review in RMD Open compiled data on eighty-one patients to evaluate the use of the interleukin-one receptor antagonist anakinra in cases resistant to intravenous immunoglobulins [9]. The review found that anakinra treatment led to the resolution of fever and systemic inflammation in approximately ninety-five percent of patients. Furthermore, complete resolution of coronary artery aneurysms was seen in nearly a third of patients, with stabilization or size reduction in over half. While the authors caution that these findings are based on heterogeneous, lower-quality evidence, they provide encouraging support for considering anakinra as a rescue therapy in refractory Kawasaki disease while we await larger, randomized controlled trials.

If you only have time for one paper this week, make it the two-year clinical outcomes of upadacitinib continuation versus withdrawal in giant cell arteritis from Annals of the Rheumatic Diseases [1]. This study provides critical, long-term evidence that extending upadacitinib therapy beyond one year drastically reduces flare rates and eliminates the need for further glucocorticoid exposure, offering a highly effective and safe steroid-sparing strategy for our giant cell arteritis patients.

Here are the key takeaways from this week in Rheumatology: First, in giant cell arteritis, extending upadacitinib fifteen milligrams daily through two years dramatically reduces flares to just seven percent and maintains steroid-free remission compared to withdrawing therapy. Second, when managing pregnant patients with systemic lupus erythematosus, look closely at the antibody profile; the combination of lupus anticoagulant and IgG isotypes of anticardiolipin or anti-beta-2-glycoprotein I carries the highest risk, nearly quadrupling adverse pregnancy outcomes. Third, comorbid fibromyalgia in lupus patients significantly increases the risk of falls and fractures, meaning we must actively screen for fibromyalgia and implement fall-prevention strategies in this population. Fourth, in systemic sclerosis, a baseline KL-6 level above one thousand units per milliliter is a strong predictor of rapid lung function decline, while elevated VCAM-1 levels identify a high-mortality vasculopathic phenotype. And finally, in obese psoriatic arthritis patients, initiating tirzepatide concurrently with biologic therapy significantly improves patient-reported outcomes, systemic inflammation, and skin clearance compared to biologics alone.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.